| 0 of 7 completed                           |  |
|--|--|
| Form Instructions                          |  |
| participant to qualify for participation i | "yes" and ALL exclusion questions #1-4 must be "no" for a n PPMI 2.0 Early Imaging. If any of these criteria are not met, a Fail form in this visit and conclude their participation in PPMI |
| Assessment Date                            |  |
| 10/12/2020                                 |  |
| Inclusion Criteria                         |  |
| 1. Enrolled in PPMI 2.0 Clinical protocol  |  |
| ○ No                                       | Yes  |
| 2. Able to provide informed consent.       |  |
| ○ No                                       | Yes  |
| 3. Women may not be pregnant, lactating    | ng or planning pregnancy during the study.   |
| ○ No                                       | Yes  |
|  | prior to injection of 18F-AV-133 on day of Baseline PET scan.<br>of non-childbearing potential or be using a highly effective method of  |

|  | that might interfere with 18F-AV-133 PET imaging: eserpine, or amphetamine derivative, within 1 month prior |  |
|--|---|--|
| ○ No   | Yes   |  |
| 2. Have current clinically significant cardiovascular disease or abnormalities on screening ECG (including but not limited to QTc > 450 msec). |   |  |
| ○ No   | Yes   |  |
| 3. Are currently taking medications that are known to cause QT-prolongation.   |   |  |
| ○ No   | Yes   |  |
| 4. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.       |   |  |
| ○ No   | Yes   |  |
|  |   |  |
| Parkinson's Disease Inclusion/Exclusion Cri  | teria MDS-UPDRS Part IB and Part II   |  |